CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA
The treatment outcomes of patients with chronic lymphocytic leukemia (CLL) have considerably improved with the introduction of targeted therapies based on Bruton kinase inhibitors (BTKIs), venetoclax, and anti-CD20 monoclonal antibodies. However, despite these consistent improvements, patients who...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2024-04-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | https://www.mjhid.org/mjhid/article/view/5696 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841561597488660480 |
|---|---|
| author | Ugo Testa Elvira Pelosi Germana Castelli Alberto Fresa Luca Laurenti |
| author_facet | Ugo Testa Elvira Pelosi Germana Castelli Alberto Fresa Luca Laurenti |
| author_sort | Ugo Testa |
| collection | DOAJ |
| description |
The treatment outcomes of patients with chronic lymphocytic leukemia (CLL) have considerably improved with the introduction of targeted therapies based on Bruton kinase inhibitors (BTKIs), venetoclax, and anti-CD20 monoclonal antibodies. However, despite these consistent improvements, patients who become resistant to these agents have poor outcomes and need new and more productive therapeutic strategies.
Among these new treatments, a potentially curative approach consists of the use of chimeric antigen receptor T (CAR-T) cell therapy, which achieved remarkable success in various B-cell malignancies, including B-cell Non-Hodgkin Lymphomas (NHLs) and B-acute lymphoblastic Leukemia (ALL). However, although CAR-T cells were initially used for the treatment of CLL, their efficacy in CLL patients was lower than in other B-cell malignancies. This review analyses the possible mechanisms of these failures. It highlights some recent developments that could offer the perspective of the incorporation of CAR-T cells in treatment protocols for relapsed/refractory CLL patients.
Keywords: Chronic Lymphoid Leukemia; CLL; CAR-T Cells; Relapsed/resistant CLL:
|
| format | Article |
| id | doaj-art-ed6dee0cb37f4a9db01ec678a57b1ec8 |
| institution | Kabale University |
| issn | 2035-3006 |
| language | English |
| publishDate | 2024-04-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-ed6dee0cb37f4a9db01ec678a57b1ec82025-01-03T01:27:40ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062024-04-0116110.4084/MJHID.2024.045CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIAUgo Testa0Elvira Pelosi1Germana Castelli2Alberto Fresa3Luca Laurenti4ISSIstituto Superiore SanitàIstituto Superiore SanitàUniversità Cattoliva.Policlinico GemelliUniversità Cattoliva. Policlinico Gemelli The treatment outcomes of patients with chronic lymphocytic leukemia (CLL) have considerably improved with the introduction of targeted therapies based on Bruton kinase inhibitors (BTKIs), venetoclax, and anti-CD20 monoclonal antibodies. However, despite these consistent improvements, patients who become resistant to these agents have poor outcomes and need new and more productive therapeutic strategies. Among these new treatments, a potentially curative approach consists of the use of chimeric antigen receptor T (CAR-T) cell therapy, which achieved remarkable success in various B-cell malignancies, including B-cell Non-Hodgkin Lymphomas (NHLs) and B-acute lymphoblastic Leukemia (ALL). However, although CAR-T cells were initially used for the treatment of CLL, their efficacy in CLL patients was lower than in other B-cell malignancies. This review analyses the possible mechanisms of these failures. It highlights some recent developments that could offer the perspective of the incorporation of CAR-T cells in treatment protocols for relapsed/refractory CLL patients. Keywords: Chronic Lymphoid Leukemia; CLL; CAR-T Cells; Relapsed/resistant CLL: https://www.mjhid.org/mjhid/article/view/5696Chronic Lymphoid Leukemia; CLLiaCAR-T Cells; CLL relapsed/refractory |
| spellingShingle | Ugo Testa Elvira Pelosi Germana Castelli Alberto Fresa Luca Laurenti CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA Mediterranean Journal of Hematology and Infectious Diseases Chronic Lymphoid Leukemia; CLLia CAR-T Cells; CLL relapsed/refractory |
| title | CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA |
| title_full | CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA |
| title_fullStr | CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA |
| title_full_unstemmed | CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA |
| title_short | CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA |
| title_sort | car t cells in chronic lymphocytic leukemia |
| topic | Chronic Lymphoid Leukemia; CLLia CAR-T Cells; CLL relapsed/refractory |
| url | https://www.mjhid.org/mjhid/article/view/5696 |
| work_keys_str_mv | AT ugotesta cartcellsinchroniclymphocyticleukemia AT elvirapelosi cartcellsinchroniclymphocyticleukemia AT germanacastelli cartcellsinchroniclymphocyticleukemia AT albertofresa cartcellsinchroniclymphocyticleukemia AT lucalaurenti cartcellsinchroniclymphocyticleukemia |